Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $24.00

Trevi Therapeutics (NASDAQ:TRVI) had its price objective boosted by Needham & Company LLC from $22.00 to $24.00 in a report published on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research firms have also recently commented on TRVI. Leerink Partners upped their target price on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Wednesday, January 21st. D. Boral Capital reiterated a “buy” rating and issued a $19.00 target price on shares of Trevi Therapeutics in a report on Monday, March 9th. Finally, Oppenheimer restated an “outperform” rating on shares of Trevi Therapeutics in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $21.60.

Trevi Therapeutics Trading Down 0.8%

Trevi Therapeutics stock opened at $10.61 on Wednesday. The company has a 50-day moving average price of $11.13 and a 200 day moving average price of $10.95. Trevi Therapeutics has a 12-month low of $4.85 and a 12-month high of $14.39. The stock has a market cap of $1.36 billion, a P/E ratio of -33.16 and a beta of 0.94.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. As a group, analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

Large investors have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC purchased a new stake in Trevi Therapeutics during the 4th quarter worth approximately $40,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Trevi Therapeutics during the 4th quarter valued at approximately $50,000. Russell Investments Group Ltd. boosted its stake in shares of Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after buying an additional 2,996 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Trevi Therapeutics by 32.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock worth $78,000 after buying an additional 1,523 shares in the last quarter. Finally, BIT Capital GmbH increased its stake in shares of Trevi Therapeutics by 32.0% in the third quarter. BIT Capital GmbH now owns 6,739 shares of the company’s stock worth $62,000 after buying an additional 1,633 shares during the last quarter. 95.76% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Trevi Therapeutics

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Trevi beat Q4 2025 EPS expectations (reported -$0.06 vs. about -$0.096), providing near-term fundamental support and likely driving early buying interest after the print. Q4 2025 earnings transcript
• Positive Sentiment: Needham raised its price target to $24, signaling continued analyst conviction and a sizable implied upside from current levels. Needham raises PT to $24
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating, adding to the roster of buy-side endorsements that may support demand in the shares. D. Boral Capital reaffirms Buy
• Positive Sentiment: JonesTrading trimmed its price target slightly (from $25 to $24) but kept a Buy rating — the change is modest and leaves a large upside implied by street targets. JonesTrading PT update
• Neutral Sentiment: Full earnings-call transcript and coverage are available for investors reviewing management commentary and execution details; useful for gauging guidance and pipeline progress but not new news by itself. Earnings transcript
• Neutral Sentiment: Analyst write-ups (e.g., Globe and Mail summary) provide context and viewpoints but do not change fundamentals immediately. Analyst insights
• Negative Sentiment: HC Wainwright cut multi-year EPS forecasts across FY2026–FY2029 (notably downgrading several yearly EPS projections) while maintaining a Buy rating and a $21 target — the lower earnings trajectory may temper enthusiasm around near-term profitability and valuation. HC Wainwright estimate revisions
• Negative Sentiment: Morgan Stanley signaled lower expectations for TRVI, adding downward pressure from a major institutional voice and contributing to intraday weakness. Morgan Stanley lowers expectations

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.